2026-07-13 FDA Warning Letter: Almon Healthcare Private Limited Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
TL;DR
The short version: On July 13, 2026, the FDA's Center for Drug Evaluation and Research issued Warning Letter 320-26-102 to Almon Healthcare Private Limited (FEI 3030509366, Ahmedabad, India) following a February 9-13, 2026 inspection, citing significant CGMP deviations for active pharmaceutical ingredients. The letter documents that the quality unit intentionally accepted mislabeled raw materials from suppliers since 2024 to circumvent licensing requirements, manufactured multiple API batches with untested materials, and shipped them to the US without proper identity testing, identity verification, or risk assessment for distributed products—constituting adulteration under 21 U.S.C. 351(a)(2)(B). The FDA found the firm's March 6, 2026 response inadequate due to lack of supporting chromatographic data, unsubstantiated analytical conclusions, absence of risk assessment for distributed batches, and failure to propose corrective actions for supplier qualification, and requested a comprehensive remediation plan addressing quality unit authority, procedure robustness, batch review oversight, and management support for quality assurance.
Argus analysis
# FDA Warning Letter Analysis: Almon Healthcare Private Limited
**Company Background and Findings**
Almon Healthcare Private Limited, a drug manufacturer located in Ahmedabad, Gujarat, India (FEI 3030509366), received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on July 13, 2026, following an inspection conducted February 9–13, 2026. The FDA identified significant deviations from Current Good Manufacturing Practice (CGMP) standards for active pharmaceutical ingredients (APIs) intended for US distribution. The inspection revealed that the facility's quality unit knowingly accepted mislabeled raw materials from suppliers since 2024 to circumvent licensing requirements, then used these untested materials in multiple API batches shipped to the United States.
**Regulatory Citations and Implications**
The violations cite section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351), which defines adulterated drugs manufactured without conformance to CGMP. The warning letter specifically addresses failures in three areas: quality unit oversight and incoming material testing (21 CFR standards for supplier qualification and identity testing); analytical method validation and stability-indicating procedures; and equipment cleaning and contamination prevention. These violations mean the APIs are legally considered adulterated and unsuitable for distribution. The letter references ICH Q7 guidance, indicating the FDA expects manufacturers to meet international CGMP standards.
**Response Requirements and Industry Monitoring**
Almon Healthcare must submit a comprehensive remediation plan addressing quality unit authority, laboratory system assessment, validated test methods, and equipment cleaning protocols. The company faces potential import detention, product recalls, and continued regulatory scrutiny. Compliance officers in the API manufacturing sector should monitor whether Almon Healthcare provides adequate scientific evidence supporting previously distributed batches and establishes interim controls for ongoing operations. The case underscores FDA's focus on intentional circumvention of quality requirements and the expectation that manufacturers maintain robust supplier qualification and analytical validation systems.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Almon Healthcare Private Limited MARCS-CMS 729291 — July 13, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Return Receipt Requested Reference #: 320-26-102 Product: Drugs Recipient: Recipient Name Mr. Rajesh Gandhi Recipient Title Chairman Almon Healthcare Private Limited Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala Ahmedabad 382240 Gujarat India Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-102 July 13, 2026 Dear Mr. Gandhi: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Almon Healthcare Private Limited, FEI 3030509366, at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, from February 9 to 13, 2026. This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your March 6, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigator observed specific deviations including, but not limited to, the following. 1. Failure of your quality unit to exercise its responsibility to ensure the API and intermediates manufactured at your facility are in compliance with CGMP. Your quality unit (QU) failed to perform identity testing on incoming raw materials used in the manufacture of APIs (b)(4) , which are intended for use in pharmacy compounding. Specifically, your firm intentionally accepted lots of (b)(4) that were deliberately mislabeled by your supplier as (b)(4) . During the inspection, your QU admitted that this was a deliberate and ongoing practice since 2024 to circumvent your firm’s lack of a required (b)(4) license. You subsequently used this mislabeled and untested material to manufacture multiple batches of (b)(4) that you ultimately shipped to the United States. Furthermore, your QU relied on your supplier’s certificate of analysis without conducting supplier qualification as your standard operating procedure requires. In your response, you acknowledge the mislabeling practice, state you have since obtained the required (b)(4) license, and commit to performing identity testing of all future lots of (b)(4) . You also state that a retrospective reevaluation of residual solvent chromatographic data confirms that peaks previously observed in the affected (b)(4) batches are attributable to (b)(4) . Your response is inadequate. Your analytical conclusions are unsubstantiated because your response does not provide the supporting chromatograms or results from your identity tests. Furtherm…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Almon Healthcare Private Limited had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Almon Healthcare Private Limited as of 2026-07-21. Argus ingests new FDA enforcement records daily.
- What FDA violations was Almon Healthcare Private Limited cited for?
- The FDA Warning Letter to Almon Healthcare Private Limited (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Almon Healthcare Private Limited?
- FDA issued the letter (MARCS-CMS 729291) on 2026-07-13 and posted it publicly on fda.gov on 2026-07-21.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-07-13 FDA Warning Letter: Almon Healthcare Private Limited Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-almon-healthcare-private-limited-2026-07-13-cgmp
"2026-07-13 FDA Warning Letter: Almon Healthcare Private Limited Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-almon-healthcare-private-limited-2026-07-13-cgmp.
Argus HQ Research. "2026-07-13 FDA Warning Letter: Almon Healthcare Private Limited Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Digital Empire Holdings LLC. Accessed July 22, 2026. https://argushq.ai/fda/warning-letter/fda-wl-almon-healthcare-private-limited-2026-07-13-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_almon_healthcare_private_limited_2026_07_13_cgmp_2026,
title = {2026-07-13 FDA Warning Letter: Almon Healthcare Private Limited Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-almon-healthcare-private-limited-2026-07-13-cgmp},
note = {Accessed: July 22, 2026}
}